Compare FINW & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | NKTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.7M | 247.4M |
| IPO Year | 2021 | 2020 |
| Metric | FINW | NKTX |
|---|---|---|
| Price | $13.72 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 15.5K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | 11.88 |
| EPS | ★ 1.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $12.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.59 | $1.63 |
| 52 Week High | $22.49 | $3.65 |
| Indicator | FINW | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.82 | 66.48 |
| Support Level | N/A | $1.88 |
| Resistance Level | $18.95 | $3.65 |
| Average True Range (ATR) | 0.67 | 0.28 |
| MACD | -0.29 | 0.01 |
| Stochastic Oscillator | 15.50 | 67.15 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.